Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.

Cancer letters - 1 May 2023

Xia Yang, Jin Rui, Li Miao, Lan Fen, Zhu Hao, Yu Yinghui, Miao Da, Wang Qiyuan, Zhou Yi, Selvaggi Giovanni, Ying Songmin, Zhang Jianjun, Shen Huahao, Le Xiuning, Li Wen

Abstract excerpt

Met proto-oncogene exon 14 skipping (METex14) mutations are targetable driver genes in approximately 3% of non-small-cell lung cancers (NSCLCs). Ensartinib, a type Ia MET inhibitor, is a multi-kinase inhibitor that has been approved for ALK-positive NSCLCs. Ensartinib was administered for compassionate use (cohort 1) and in a phase II clinical trial (cohort 2) to patients with METex14 mutant NSCLCs, with ORR as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 36948240
DOI: 10.1016/j.canlet.2023.216140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.PMID 36948240Read ↗

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialSemantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.Semantic proximity Read ↗

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.Semantic proximity Read ↗

New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).Semantic proximity Read ↗

A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.